Artrya Expands Global Footprint in Heart Disease AI
Company Announcements

Artrya Expands Global Footprint in Heart Disease AI

Artrya Limited (AU:AYA) has released an update.

Artrya Limited has initiated commercial operations in Australia, partnering with The Cardiac Centre NSW, and is extending its U.S. presence through strategic partnerships, ahead of anticipated FDA approval. The company, specialized in AI-based coronary artery disease diagnosis, is also exploring new markets following TGA approval. With a strong cash position, Artrya expects to generate first revenues in Australia in the next quarter and is advancing its commercialization efforts with pilot programs in various jurisdictions.

For further insights into AU:AYA stock, check out TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App